CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells

PURPOSE: T cells engineered with chimeric antigen receptors (CARs) recognizing CD19 can induce complete remission of B cell malignancies in clinical trials; however, in some disease settings CAR therapy confers only modest clinical benefit due to attenuated persistence of CAR T cells. The purpose of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Wang, Xiuli, Wong, ChingLam W., Urak, Ryan, Mardiros, Armen, Budde, Lihua E., Chang, Wen-Chung, Thomas, Sandra H., Brown, Christine E., La Rosa, Corinna, Diamond, Don J, Jensen, Michael C., Nakamura, Ryotaro, Zaia, John A, Forman, Stephen J.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4489991/
https://ncbi.nlm.nih.gov/pubmed/25838392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2920
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars